SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data from the ENCIRCLE single-arm pivotal trial achieved all primary and secondary endpoints for safety and effectiveness, with outcomes simultaneously published in The Lancet. Thirty-day data from the EVOQUE system STS/ACC TVT Registry, the largest real-world transcatheter tricuspid valve replacement. ...

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve performance and durability. Separately, 10-year results from PARTNER 2 intermediate risk studies reinforce Edwards' leadership in setting the standard for lasting valve performance and excellent patien. ...

New York, New York--(Newsfile Corp. - October 23, 2025) - Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW).If you currently own shares of Edwards stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=29704 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenl ...

Oct 23, 2025 7:05 AM Eastern Daylight Time Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025 Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. Contacts Media Contact: Amy Meshulam, 949-250-4009Investor Contact: Mark Wilterding, 949-250-6826 Industry: Edwards Lifesciences Corporation Share IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to a ...

Edwards Lifesciences Corporation (NYSE:EW) ranks among the best medical device stocks to invest in. Piper Sandler maintained its Overweight rating and $90 price target for Edwards Lifesciences Corporation (NYSE:EW) on October 7, ahead of the expected 7-year findings from Edwards’ PARTNER 3 study, which is set to be presented on October 27 at the Transcatheter Cardiovascular Therapeutics (TCT) conference. With follow-up spanning ten years, Edwards’ historic PARTNER 3 trial compares surgical aortic valve r ...

财报发布安排 - 爱德华兹生命科学公司计划于2025年10月30日美股市场收盘后公布第三季度业绩 [1] - 在上一季度，公司调整后每股收益为67美分，比Zacks共识预期高出8.06% [1] - 在过去四个季度中，公司每股收益三次超出预期，一次符合预期，平均超出幅度为5.50% [1] 第三季度业绩预期 - 第三季度营收的Zacks共识预期为15亿美元，暗示较去年同期公布的数据增长11.5% [2] - 每股收益59美分的共识预期表明较去年同期公布的数据下降11.9% [2] - 在过去30天内，每股收益预期维持在59美分不变 [3] 各业务板块表现预期 - 经导管主动脉瓣置换业务预计表现强劲，主要得益于其市场领先的SAPIEN 3 Ultra RESILIA平台在美国的强势表现以及该平台在欧洲的持续扩张 [4] - 公司已将该业务2025年销售增长指引上调至6-7%，模型预计TAVR销售额为11.1亿美元，同比增长8.5% [5] - 经导管二尖瓣和三尖瓣治疗业务预计因修复和置换技术组合的实力而得到支撑，PASCAL修复系统预计在美国、欧洲及全球获得增长动力 [6] - EVOQUE三尖瓣置换系统的商业发布可能在美国和欧洲持续推进，模型预计TMTT业务营收为1.341亿美元，较去年同期大幅改善47.2% [7] - 外科结构性心脏业务预计表现强劲，受其高端RESILIA产品组合的全球采纳推动，模型预计该部门营收为2.567亿美元，较去年同期小幅增长7% [10] 其他医疗科技公司业绩展望 - Exact Sciences目前具有+32.65%的收益ESP和Zacks排名第1，预计第三季度每股收益将较去年同期增长147.6% [13][14] - ANI Pharmaceuticals目前具有+1.15%的收益ESP和Zacks排名第1，预计第三季度每股收益将较去年同期飙升29.9% [14][15] - IDEXX Laboratories目前具有+0.23%的收益ESP和Zacks排名第2，预计第三季度每股收益将较去年同期增长12.1% [15][16]

公司概况 - 公司全称为爱德华兹生命科学，在纽约证券交易所上市，股票代码为EW [1] - 公司成立于1958年，总部位于美国加利福尼亚州尔湾市 [1] - 公司是设计和商业化治疗晚期心血管疾病创新技术的领导者 [1] 业务与产品 - 公司主要专注于治疗晚期心血管疾病的创新技术 [1]

公司概况 - 公司全称为Edwards Lifesciences Corporation，在纽约证券交易所上市，股票代码为EW [1] - 公司成立于1958年，总部位于美国加利福尼亚州尔湾市 [1] - 公司是设计和商业化先进心血管疾病治疗创新技术的领导者 [1] 业务与产品 - 公司主要业务集中于治疗晚期心血管疾病的创新技术 [1]

NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW). SO WHAT: If you currently own shares of Edwards stock, please visit the firm’s website at https://rosenlegal.com/submit-form/?case_id=29704 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenlega ...

主要升级 - Seaport Research将Constellation Energy (CEG)评级从中性上调至买入，目标价407美元，预计年底前将有更多数据中心电力交易公告、并购活动以及热力独立发电商的积极盈利修正 [2] - Wolfe Research将Otis Worldwide (OTIS)评级从同业持平上调至跑赢大盘，目标价109美元，认为其第四季度展望的下行风险已被广泛预期，并存在抵消性的积极发展因素 [3] - JPMorgan将Ionis Pharmaceuticals (IONS)评级从中性上调至增持，目标价从49美元大幅上调至80美元，认为公司多项产品上市使其处于盈亏平衡路径上 [4] - Needham将Penumbra (PEN)评级从持有上调至买入，目标价326美元，预计由于Thunderbolt和Ruby XL产品即将推出、STORM-PE试验结果以及中国区不利因素缓解，公司2026年增长将显著加速 [4] - Deutsche Bank将Northrop Grumman (NOC)评级从持有上调至买入，目标价从575美元上调至700美元，预计在2028年后随着B-21轰炸机项目实现现金盈利和Sentinel武器系统接近生产阶段，公司将产生强劲的自由现金流 [5] 主要降级 - HSBC将Intel (INTC)评级从持有下调至减持，目标价从21.25美元上调至24美元，认为尽管短期交易公告可能推高股价，但公司自身晶圆厂执行力是可持续扭亏为盈的关键，当前股价重估过度 [6] - JPMorgan将FedEx (FDX)评级从增持下调至中性，目标价从284美元下调至274美元，基于对零担货运行业的最新渠道调查，认为其货运部门在分类加总估值法中应适用较低估值倍数 [6] - Oppenheimer将Edwards Lifesciences (EW)评级从跑赢大盘下调至持平，未给出目标价，尽管第三方数据暗示第三季度TAVR业务有上行潜力，但此次降级更多基于结构性因素而非短期表现 [6] - BofA将Freshpet (FRPT)评级从买入下调至中性，目标价从81美元大幅下调至60美元，指出过去六个月宠物食品类别（尤其是狗粮）增长恶化，因宠物收养速度放缓且消费者支出缩减 [6] - Oppenheimer将Incyte (INCY)评级从跑赢大盘下调至持平，目标价从81美元微调至82美元，降级原因是市场对Opzelura、povorcitinib、mCALR、CDK2i等产品以及新管理层的期望过高 [6]